GE HealthCare has reported a net income of $428m, or $0.93 per diluted share, for the second quarter ended 30 June 2024, a 2% rise compared to $418m, or $0.91 per diluted share, for the respective period in 2023.
The company’s net income for the second quarter of 2024 (Q2 2024) increased by 14% compared to $374m, or $0.81 per diluted share, for the first quarter of 2024 (Q1 2024).
GE HealthCare reported a total revenue of $4.83bn for Q2 2024, a 0.5% rise compared to $4.81bn for the same quarter in 2023, and a 4% increase compared to $4.65bn for Q1 2024.
GE HealthCare reported operating expenses of $1.39bn for Q2 2024, a 1.8% rise compared to $1.37bn for the respective quarter in the previous year.
The health technology company reported an income before tax of $578m for Q2 2024, a 1.5% increase compared to $570m for the same period in 2023.
GE HealthCare president and CEO Peter Arduini said: “In the second quarter, we delivered year-over-year sales growth and margin expansion despite headwinds in the China market.
“We also reported solid orders growth with particular strength in the U.S., as healthcare systems invest in technologies that enhance patient care and improve productivity.
“We are pleased with our continued progress in advancing our margin goals, while continuing our investments for future growth.”
GE HealthCare has reported a net income of $802m, or $1.75 per diluted share, for the first six months ended 30 June 2024, a 32% rise compared to $607m, or $1.33 per diluted share, for the respective period in 2023.
The health technology company reported a total revenue of $9.49bn for the first half of 2024 (H1 2024), a 0.3% decline compared to $9.52bn for the same period in 2023.
It has reported operating expenses of $2.75bn for H1 2024, a 2% rise compared to $2.7bn for the corresponding period in the previous year.
The company reported an income before tax of $1.09bn for H1 2024, a 2% increase compared to $1.11bn for the same period in 2023.
Recently, GE HealthCare partnered with Amazon Web Services (AWS) to develop foundation models and generative AI (Gen AI) tools to help enhance medical diagnostics and patient care.
